| Bioactivity | Troriluzole hydrochloride is a third-generation peptide precursor of Riluzole (HY-B0211) and is an orally active glutamate modulator. Troriluzole hydrochloride can reduce synaptic glutamate levels and enhance the uptake of synaptic glutamate. Troriluzole hydrochloride shows potential for treating Alzheimer's disease and Generalized Anxiety Disorder (GAD) [1][2]. |
| CAS | 1926204-76-3 |
| Formula | C15H17ClF3N5O4S |
| Molar Mass | 455.84 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Schanzer B, et al. Novel investigational therapeutics for generalized anxiety disorder (GAD). Expert Opin Investig Drugs. 2019 Nov;28(11):1003-1012. [2]. Huang LK, et al. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020 Jan 6;27(1):18. |
Troriluzole hydrochloride
CAS: 1926204-76-3 F: C15H17ClF3N5O4S W: 455.84
Troriluzole hydrochloride is a third-generation peptide precursor of Riluzole (HY-B0211) and is an orally active glutama
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.